Clinical Trials Browser

Phase 1/2 × cytokine inducible SH2-containing protein × Clear all

NCT04493099 2020-11-12

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute